Pharmaceutical - Quick Overview

                         Cipla Ltd

Cipla Ltd  (updated - 29 April 2009)
Lower than expected foreign exchange losses and higher technology licence fees have boosted Cipla’s net profits for the March 2009 quarter. After a strong growth in the top line in previous quarters, net sales were up just over 14 per cent at Rs 1,235 crore. While the growth in domestic formulations of close to 16 per cent was better than the industry’s performance, the drug major’s exports were rather disappointing given that the rupee has depreciated by over 20 per cent during the quarter.

Export formulations grew at just over 17 per cent way below the 36 per cent clocked in the nine months to December 2008. Thus, while Cipla was widely expected to grow its net profits in 2008-09 by about 12-14 per cent, theyhave risen just under 10 per cent to Rs 768 crore.The management is understood to have indicated that revenues and profits would grow by about 10 per cent in the current year on a constant currency basis.

That is somewhat conservative given that the home market is growing at a fairly brisk pace. At Rs 240, the stock trades at around 18 times estimated earnings for 2009-10, which, analysts say is somewhat expensive given the subdued earnings growth outlook.
source - businessstandard

Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but does not warrant or guarantee their accuracy or date.
Our site takes no responsibility for any investment decisions based on recommendations provided on website.